Today the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan (USask) announced positive interim results from their Phase 1 clinical trial for COVAC-2, VIDOs COVID-19 subunit vaccine candidate.
The interim data from the study led by the Canadian Centre for Vaccinology (CCfV) demonstrates COVAC-2 is safe and well tolerated. The most common general reaction reported was a headache and the most notable local reaction was mild injection site pain. These reactions are common after most immunizations….
